- Home
- TCRX vs RMAX Comparison
TCRX vs RMAX Comparison
Compare TCRX & RMAX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- TCRX
- RMAX
- Stock Information
- Founded
- TCRX 2018
- RMAX 1973
- Country
- TCRX United States
- RMAX United States
- Employees
- TCRX N/A
- RMAX N/A
- Industry
- TCRX Biotechnology: Pharmaceutical Preparations
- RMAX Real Estate
- Sector
- TCRX Health Care
- RMAX Finance
- Exchange
- TCRX Nasdaq
- RMAX Nasdaq
- Market Cap
- TCRX 170.1M
- RMAX 200.2M
- IPO Year
- TCRX 2021
- RMAX 2013
- Fundamental
- Price
- TCRX $2.40
- RMAX $9.99
- Analyst Decision
- TCRX Strong Buy
- RMAX Hold
- Analyst Count
- TCRX 5
- RMAX 4
- Target Price
- TCRX $11.40
- RMAX $9.17
- AVG Volume (30 Days)
- TCRX 544.4K
- RMAX 161.7K
- Earning Date
- TCRX 03-05-2025
- RMAX 02-20-2025
- Dividend Yield
- TCRX N/A
- RMAX N/A
- EPS Growth
- TCRX N/A
- RMAX N/A
- EPS
- TCRX N/A
- RMAX N/A
- Revenue
- TCRX $9,362,000.00
- RMAX $311,818,000.00
- Revenue This Year
- TCRX N/A
- RMAX N/A
- Revenue Next Year
- TCRX $5.14
- RMAX $0.85
- P/E Ratio
- TCRX N/A
- RMAX N/A
- Revenue Growth
- TCRX N/A
- RMAX N/A
- 52 Week Low
- TCRX $2.38
- RMAX $6.94
- 52 Week High
- TCRX $9.69
- RMAX $14.31
- Technical
- Relative Strength Index (RSI)
- TCRX 25.27
- RMAX 39.50
- Support Level
- TCRX $2.60
- RMAX $10.25
- Resistance Level
- TCRX $2.85
- RMAX $10.28
- Average True Range (ATR)
- TCRX 0.17
- RMAX 0.42
- MACD
- TCRX 0.00
- RMAX 0.00
- Stochastic Oscillator
- TCRX 2.41
- RMAX 46.45
About TCRX TScan Therapeutics Inc.
TScan Therapeutics Inc is a biopharmaceutical company focused on the development of T-cell receptor (TCR) engineered T cell therapies (TCR-T) for the treatment of patients with cancer. The company's liquid tumor TCR-T therapy candidates, TSC-100 and TSC-101, are in development for the treatment of patients with hematologic malignancies to eliminate residual leukemia and prevent relapse after hematopoietic stem cell transplantation. It is also developing multiplexed TCR-T therapy candidates for the treatment of various solid tumors.
About RMAX RE/MAX Holdings Inc.
RE/MAX Holdings Inc operates as a franchisor of real estate brokerage services. It recruits and retains agents and sells franchises. The company's operating segments include Real Estate, Mortgage, Marketing Funds, and Others. It generates maximum revenue from the Real Estate segment.